Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application

Orenstein, Arie; Kostenich, Genady; Tsur, Haggai; Kogan, Leonid; Malik, Zvi

doi:10.1016/0304-3835(95)03814-d

Cited by 53 publications

(32 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following their conclusions, if the hyperthermia effect is high enough to contribute to the therapeutic process, the induction of the synergistic effect may have taken place, enhancing tissue damage during PDT. 15 Our results showed that mild hyperthermia ͑about 40-42°C͒ was observed, having only marginal influence for most results. Observed effects due to other factors, rather than PDT, will be discussed within the model discussion subsection.…”

Section: Resultsmentioning

confidence: 59%

See 1 more Smart Citation

Possibility for a full optical determination of photodynamic therapy outcome

Vollet‐Filho¹,

Menezes²,

Moriyama³

et al. 2009

Journal of Applied Physics

View full text Add to dashboard Cite

The microfluidic system for studies of carcinoma and normal cells interactions after photodynamic therapy (PDT) procedures Biomicrofluidics 5, 041101 (2011) Drug injection into fat tissue with a laser based microjet injector J. Appl. Phys. 109, 093105 (2011) A near infrared instrument to monitor relative hemoglobin concentrations of human bone tissue in vitro and in vivo Rev. Sci. Instrum. 81, 043111 (2010) Mechanism of oxidative stress generation in cells by localized near-infrared femtosecond laser excitation Appl. Phys. Lett. 95, 233702 (2009) Probing nanoantenna-directed photothermal destruction of tumors using noninvasive laser irradiation Appl. Phys. Lett. 95, 233701 (2009) Additional information on J. Appl. Phys. The efficacy of photodynamic therapy ͑PDT͒ depends on a variety of parameters: concentration of the photosensitizer at the time of treatment, light wavelength, fluence, fluence rate, availability of oxygen within the illuminated volume, and light distribution in the tissue. Dosimetry in PDT requires the congregation of adequate amounts of light, drug, and tissue oxygen. The adequate dosimetry should be able to predict the extension of the tissue damage. Photosensitizer photobleaching rate depends on the availability of molecular oxygen in the tissue. Based on photosensitizers photobleaching models, high photobleaching has to be associated with high production of singlet oxygen and therefore with higher photodynamic action, resulting in a greater depth of necrosis. The purpose of this work is to show a possible correlation between depth of necrosis and the in vivo photosensitizer ͑in this case, Photogem®͒ photodegradation during PDT. Such correlation allows possibilities for the development of a real time evaluation of the photodynamic action during PDT application. Experiments were performed in a range of fluence ͑0 -450 J / cm 2 ͒ at a constant fluence rate of 250 mW/ cm 2 and applying different illumination times ͑0-1800 s͒ to achieve the desired fluence. A quantity was defined ͑ ͒ as the product of fluorescence ratio ͑related to the photosensitizer degradation at the surface͒ and the observed depth of necrosis. The correlation between depth of necrosis and surface fluorescence signal is expressed in and could allow, in principle, a noninvasive monitoring of PDT effects during treatment. High degree of correlation is observed and a simple mathematical model to justify the results is presented.

show abstract

Section: Resultsmentioning

confidence: 59%

“…This type of temperature variation is compatible with observations already reported in the literature. 15 Such final temperature can be seen as indicative of a slight occurrence of hyperthermia, specially for prolonged appliance of illumination.…”

Section: H Monitoring the Thermal Effects In The Pdt Proceduresmentioning

confidence: 99%

Possibility for a full optical determination of photodynamic therapy outcome

Vollet‐Filho¹,

Menezes²,

Moriyama³

et al. 2009

Journal of Applied Physics

View full text Add to dashboard Cite

show abstract

“…During PDT, pain often manifests as a burning sensation and usually peaks in the first minutes of treatment, tending to stabilize or even decrease by the end of it. 6 The Visual Analogue Scale (VAS) is the most widely used method to measure pain, in which the patient indicates their pain intensity on a scale of zero to ten. Most studies agree that about twenty percent of the patients undergoing PDT rate pain over six on this scale, which is considered an important level.…”

Section: Introductionmentioning

confidence: 99%

Pain in photodynamic therapy: mechanism of action and management strategies

Chaves

Torezan

Niwa

et al. 2012

An. Bras. Dermatol.

View full text Add to dashboard Cite

Photodynamic therapy involves administration of a photosensitizing drug and its subsequent activation by irradiation with a light source at wavelengths matching the absorption spectrum of the photosensitizer. In many countries around the world, topical photodynamic therapy has been approved for treatment of cutaneous oncologic conditions such as actinic keratosis, Bowen's disease, and superficial basal cell carcinoma. Multicenter, randomized, controlled studies have confirmed its efficacy and superior cosmetic outcomes compared to conventional therapies. Nevertheless, this therapeutic method presents some adverse effects, such as erythema, edema, pigmentation, pustules, and pain. There is no doubt that pain is the most severe of the adverse effects, being sometimes responsible for definitive treatment interruption. The pain mechanism has not yet been fully understood, which makes complete pain control a challenge to be conquered. In spite of that, this literature review presents some useful pain management strategies as well as the most important pain-related factors in photodynamic therapy. Keywords: Pain, referred; Photochemotherapy; Photosensitizing agents Resumo: A terapia fotodinâmica consiste na administração de uma droga fotossensibilizante e sua subseqüente irradiação com uma fonte de luz de espectro correspondente ao do seu fotossensibilizador. Em diversos países do mundo, a terapia fotodinâmica tópica é aprovada para o tratamento de condições oncológicas cutâneas como queratoses actínicas, doença de Bowen e carcinoma basocelular superficial. Estudos multicêntricos controlados e randomizados confirmam sua eficácia e seus resultados cosméticos superiores em relação às terapias convencionais. No entanto, existem alguns efeitos adversos inerentes a esse método terapêutico, como eritema, edema, pigmentação, pústulas e dor. Essa última é, sem dúvida, a mais importante deles, chegando a ser responsável pela interrupção definitiva do tratamento em alguns casos. O mecanismo dessa dor permanece ainda não completamente entendido. Tal fato faz do controle total da dor durante a terapia fotodinâmica um desafio ainda a ser conquistado. Apesar disso, esta revisão apresenta algumas estratégias que podem ajudar os pacientes a tolerar melhor a terapia fotodinâmica, além de relacionar os principais fatores ligados à dor descritos na literatura.

show abstract

“…The power of elevated activity of PBGD to produce PpIX was clinically demonstrated for malignant gliomas (Stummer et al, 1998b); oral cavity cancer (Leunig et al, 2000a); colonic and gastrointestinal dysplasia (Stepp et al, 1998); peritoneal endometriosis (Hillemanns et al, 2000); laryngeal neoplasms (Leunig et al, 2000b); malignant lesions of the oesophagus (Hinnen et al, 1998); lower urinary tract tumours (Kriegmair et al, 1999); bladder cancer (Kriegmair et al, 1996); malignant mucosa in head and neck cancer (Betz et al, 1999); Barrett's oesophagus and adenocarcinoma (Stepp et al, 1998); basal and squamous cell carcinoma (Orenstein et al, 1995(Orenstein et al, , 1996(Orenstein et al, , 1997Malik et al, 1998) and coetaneous lymphoma (Orenstein et al, 2000).…”

Section: Discussionmentioning

confidence: 99%

Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?

et al. 2002

View full text Add to dashboard Cite

Recently, considerable interest has been directed to red-fluorescence photodiagnosis of brain and other tumours during surgery using the protoporphyrin IX natural precursor, 5-aminolaevulinic acid. In the present study we focused on the role of the rate-limiting enzyme porphobilinogen deaminase in glioma C6 cell activity, differentiation and sub-cellular distribution. Over-expression of the human housekeeping porphobilinogen deaminase in the glioma cells, using the housekeepingporphobilinogen deaminase plasmid, induced a G1 cell cycle attenuation accompanied by increases in enzyme activity and c6 differentiation toward astrocytes. Visualisation of subcellular localisation of the porphobilinogen deaminase using the independent techniques of fluorescence immuno-staining with specific anti-human porphobilinogen deaminase antibodies and cellular expression of porphobilinogen deaminase fused to green fluorescent protein, revealed (unexpectedly) a major fraction of porphobilinogen deaminase in the nucleus and only a minor fraction in the cytoplasm. Both C and N terminals of porphobilinogen deaminase fused to green fluorescent protein revealed a major fraction of the newly synthesized fused porphobilinogen deaminase in the nucleus. Furthermore, newborn rat brain cells grown in a primary culture showed the same localisation pattern of porphobilinogen deaminase in the nuclei. Stimulation of C6 glioma cell differentiation by butyrate induced a marked decrease in porphobilinogen deaminase both in the nucleus and in the cytoplasm as determined by Western blotting and fluorescence immuno-localisation. These findings suggest a possible dual role for housekeeping porphobilinogen deaminase in fast dividing glioma cells, one related to the porphyrin synthesis pathway and another coupled to nuclear function, which might be linked to tumorigenesis.

show abstract

Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application

Cited by 53 publications

References 9 publications

Possibility for a full optical determination of photodynamic therapy outcome

Possibility for a full optical determination of photodynamic therapy outcome

Pain in photodynamic therapy: mechanism of action and management strategies

Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?

Contact Info

Product

Resources

About